(19)
(11) EP 3 261 673 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
17.03.2021 Bulletin 2021/11

(45) Mention of the grant of the patent:
06.01.2021 Bulletin 2021/01

(21) Application number: 16706528.3

(22) Date of filing: 22.02.2016
(51) International Patent Classification (IPC): 
A61K 41/00(2020.01)
A61K 38/16(2006.01)
A61N 5/10(2006.01)
A61K 47/64(2017.01)
(86) International application number:
PCT/EP2016/000303
(87) International publication number:
WO 2016/134838 (01.09.2016 Gazette 2016/35)

(54)

COMBINED VACCINATION/RADIOTERAPY FOR CANCER TREATMENT

KOMBINIERTE IMPFUNGS-/STRAHLENTHERAPIE ZUR KREBSBEHANDLUNG

VACCINATION/RADIOTHÉRAPIE COMBINÉES POUR LE TRAITEMENT DU CANCER


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 23.02.2015 WO PCT/EP2015/000507

(43) Date of publication of application:
03.01.2018 Bulletin 2018/01

(73) Proprietors:
  • Institut Curie
    75005 Paris (FR)
  • Centre National de la Recherche Scientifique (C.N.R.S.)
    75794 Paris Cedex 16 (FR)
  • Institut Gustave Roussy
    94805 Villejuif Cédex (FR)
  • Assistance Publique-Hôpitaux de Paris (APHP)
    75004 Paris (FR)
  • Institut National de la Santé et de la Recherche Médicale
    75654 Paris 13 (FR)
  • Université de Paris
    75006 Paris (FR)

(72) Inventors:
  • DEUTSCH, Eric
    75004 Paris (FR)
  • LUDGER, Johannes
    92400 Courbevoie (FR)
  • MONDINI, Michèle
    75013 Paris (FR)
  • NIZARD, Mevyn
    94260 Fresnes (FR)
  • PERFETTINI, Jean-Luc
    77100 Meaux (FR)
  • TARTOUR, Eric
    75003 Paris (FR)
  • TRAN, Thi
    75018 Paris (FR)

(74) Representative: Barbot, Willy 
Simodoro-ip 82, rue Sylvabelle
13006 Marseille
13006 Marseille (FR)


(56) References cited: : 
EP-A1- 2 740 491
WO-A2-2012/177624
   
  • HAICHEUR N ET AL: "The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 165, no. 6, 15 September 2000 (2000-09-15), pages 3301-3308, XP002228666, ISSN: 0022-1767 cited in the application
  • REBECCA G. POMERANTZ ET AL: "The role of epidermal growth factor receptor in head and neck squamous cell carcinoma", CURRENT ONCOLOGY REPORTS, vol. 5, no. 2, 1 April 2003 (2003-04-01), pages 140-146, XP055205530, ISSN: 1523-3790, DOI: 10.1007/s11912-003-0101-z
  • R. HASSAN: "Tumor-Directed Radiation and the Immunotoxin SS1P in the Treatment of Mesothelin-Expressing Tumor Xenografts", CLINICAL CANCER RESEARCH, vol. 12, no. 16, 15 August 2006 (2006-08-15), pages 4983-4988, XP055157621, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-06-0441
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).